Among patients with wild-type tumors, PTL likely impacts outcomes through other activating mutations such as BRAF V600E, which is not only largely mutually exclusive of KRAS and associated with poor prognosis but is also encountered far more frequently in RS disease. This evidence concerns the gene KRAS and X-linked retinoschisis.